Long term changes in platelet counts after H. pylori eradication in non-ITP patients

Platelets

Volumn 21, Issue 8, 2010, Pages 628-631

  Matsukawa, Yoshihiro ^a   Iwamoto, Maho ^b   Kato, Kimitoshi ^b   Mizuno, Shigeaki ^b   Gon, Yasuhiro ^c   Hemmi, Akihiro ^a   Shirinskaya, Natalia ^d   Takeuchi, Jin ^a   Sawada, Shigemasa ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Division of Gastroenterology and Hepatology   (Japan)

^c Department of Advanced Medical Science   (Japan)

^d Omsk State Medicl Diagnostic Center   (Russian Federation)

Author keywords

Eradication; gastroduodenoscopy; Helicobacter pylori; platelet

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; IMMUNOGLOBULIN G ANTIBODY; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANTIBODY TITER; ARTICLE; CIGARETTE SMOKING; DUODENOSCOPY; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; SEROLOGY; STOMACH ULCER; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 78149425411     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.510894     Document Type: Article

References (16)

1. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel B. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2009;113:1231-1240.
2. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, Volzone F, Jovic G, Leonardi G, Donelli A, et al. Helicobacter pylori infection and chronic immune thrombocy-topenic purpura: Long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007;110:3833-3841. (Pubitemid 350248438)
3. Satake M, Nishikawa J, Fukagawa Y, Akashi K, Okamoto T, Yoshida T, Hirano A, Maetani N, Iida Y, Sakaide I. The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007;22:2233-2237. (Pubitemid 350145628)
4. Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Nakao T, Koh K, Watanabe T, Fujiwara Y, et al. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol 2009;88:789-793.
5. Matsukawa Y, Kato K, Hatta Y, Iwamoto M, Mizuno S, Kurihara R, Arakawa Y, Kurosaka H, Hayashi I, Sawada S. Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura. Platelets 2007;18:52-55. (Pubitemid 46269615)
6. Matsukawa Y, Kurosaka H, Kato K, Hayashi I, Minekawa K, Arakawa Y, Sawada S. Lansoprazole increases serum IgG and IgM in H. pylori-infected patients. Int J Immunopathol Pharmacol 2007;20:173-179. (Pubitemid 46506889)
7. Tell GS, Grimm Jr RH, Vellar D, Theodorsen L. The relationship of white cell count, platelet count, and hematocrit to cigarette smoking in adolescents: The Oslo Youth Study. Circulation 1985;72:971-974. (Pubitemid 16205395)
8. Schwartz J, Weis ST. Cigarette smoking and peripheral blood leukocyte differentials. Ann Epidemiol 1994;4:236-242. (Pubitemid 24154303)
9. Matsukawa Y, Tomita Y, Nishinarita S, Horie T, Kato K, Arakawa Y, Ko K, Shimada H, Nakano M, Kitami Y, et al. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: Endoscopic evalu-ation ofulcer healing. J Int Med Res 1997;25:190-195. (Pubitemid 27379686)
10. Dixon M, Genta RM, Yardley JH, Correa P. The updated Sydney system. Am J Surg Pathol 1996;20:1161-1181.
11. Wakae T, Takatsuka H, Mori A, Okada M, Okamoto T, Hara H, Kakishita E. Influence of Helicobacter pylori on platelets after bone marrow transplantation from unrelated donors. Bone Marrow Transplant 2003;31:493-496. (Pubitemid 36511817)
12. Ozel AM, Demirturk L, Aydogdu A, Gultepe M, Yazgan Y, Imizalioglu N, Gurbuz AK, Narin Y. Effect of Helicobacter pylori infection and eradication therapy on interleukin-6 levels in patients with familial mediterranean fever. Int J Clin Pract 2008;62:754-761. (Pubitemid 351533657)
13. Ferrero RL. Innate immune recognition of the extracellular mucosal pathogen, Helicobacter pylori. Mol Immunol 2005;42:879-885.
14. Leslie M. Beyond clotting: The powers ofplatelets. Science 2010;328:562-564.
15. Aslam R, Speck ER, Kim M, Crow AR, Bang KWA, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet Toll-like receptor expression modulate lipopolysaccharide-induced thrombocytopenia and tumor nexcrosis factor-α production in vivo. Blood 2006;107:637-641. (Pubitemid 43076388)
16. Scott T, Owens MD. Thrombocytes respond to lipopolysac-charide through Toll-like-4 and MAP kinase and NF-B pathways leading to expression of interleukin-6 and cycloox-ygenase-2 with production of prostaglandin E2. Mol Immunol 2008;45:1001-1008. (Pubitemid 350016336)